Charles Rai

“I wanted to talk about sort of overall performance for the business because, you know, obviously we now have these different subgroups, you know, PTR, Pharma Direct subscriptions, and each of these has There's different kind of metrics, but ultimately at the end of the day, is it right to think that people are going…”

“I know people ask about your expectations on pass-throughs within the guide. Maybe can you give us a sense on what your assumption for direct fee revenue progression maybe through the rest of the year relative to what we've seen so far in the first half?”

“Maybe just sticking with sort of the pharma segment and sort of thinking about the guide for the second half. If we look at the first half performance, I think AOI growth was up 28%.”

“You may asked your question yeah thanks for taking the question first one just on a clarification is just I think Brian you kind of mentioned that with the settlement the timing of the settlement requirements is that aligned with the launch of the the new rebate free model is the first just sort of clarification…”

“And also, obviously, John and Kurt, congrats on the new roles. A lot of hard work done here, so congrats.”